Effectiveness and cost-effectiveness of reactive, targeted indoor residual spraying for malaria control in low-transmission settings: a cluster-randomised, non-inferiority trial in South Africa. Issue 10276 (27th February 2021)

• Record Type: Journal Article
• Authors: Bath, David; Cook, Jackie; Govere, John; Mathebula, Phillemon; Morris, Natashia; Hlongwana, Khumbulani; Raman, Jaishree; Seocharan, Ishen; Zitha, Alpheus; Zitha, Matimba; Mabuza, Aaron; Mbokazi, Frans; Machaba, Elliot; Mabunda, Erik; Jamesboy, Eunice; Biggs, Joseph; Drakeley, Chris; Moonasar, Devanand; Maharaj, Rajendra; Coetzee, Maureen; Pitt, Catherine; Kleinschmidt, Immo
• Is Part Of: Lancet. Volume 397:Issue 10276(2021)
• Page Start: 816
• Page End: 827
• Publication Date: 2021-02-27
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Medicine; Electronic journals; Periodicals; 610.5
• DOI: 10.1016/S0140-6736(21)00251-8
• Languages: English
• ISSNs: 0140-6736

Abstract

Summary: Background: Increasing insecticide costs and constrained malaria budgets could make universal vector control strategies, such as indoor residual spraying (IRS), unsustainable in low-transmission settings. We investigated the effectiveness and cost-effectiveness of a reactive, targeted IRS strategy. Methods: This cluster-randomised, open-label, non-inferiority trial compared reactive, targeted IRS with standard IRS practice in northeastern South Africa over two malaria seasons (2015–17). In standard IRS clusters, programme managers conducted annual mass spray campaigns prioritising areas using historical data, expert opinion, and other factors. In targeted IRS clusters, only houses of index cases (identified through passive surveillance) and their immediate neighbours were sprayed. The non-inferiority margin was 1 case per 1000 person-years. Health service costs of real-world implementation were modelled from primary and secondary data. Incremental costs per disability-adjusted life-year (DALY) were estimated and deterministic and probabilistic sensitivity analyses conducted. This study is registered with ClinicalTrials.gov, NCT02556242 . Findings: Malaria incidence was 0·95 per 1000 person-years (95% CI 0·58 to 1·32) in the standard IRS group and 1·05 per 1000 person-years (0·72 to 1·38) in the targeted IRS group, corresponding to a rate difference of 0·10 per 1000 person-years (–0·38 to 0·59), demonstrating non-inferiority for targeted IRS (p<0·0001). Per additional DALY incurred, targeted IRS saved US$7845 (2902 to 64 907), giving a 94–98% probability that switching to targeted IRS would be cost-effective relative to plausible cost-effectiveness thresholds for South Africa ($2637 to $3557 per DALY averted). Depending on the threshold used, targeted IRS would remain cost-effective at incidences of less than 2·0–2·7 per 1000 person-years. Findings were robust to plausible variation in other parameters. Interpretation: Targeted IRS was non-inferior, safe, less costly, and cost-effective compared with standard IRS in this very-low-transmission setting. Saved resources could be reallocated to other malaria control and elimination activities. Funding: Joint Global Health Trials.